Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335764 · ClinicalTrials.gov registry record · Phase 1
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT00335764: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00335764 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 92 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00335764, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
This phase I/II trial is studying the side effects and best dose of erlotinib, tipifarnib, and temsirolimus when given together with sorafenib and to see how well they work in treating patients with recurrent glioblastoma multiforme or gliosarcoma. Sorafenib, erlotinib, tipifarnib, and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib and tipifarnib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with erlotinib, tipifarnib, or temsirolimus may kill more tumor cells.
Interventions
- DRUG erlotinib hydrochloride
- DRUG sorafenib tosylate
- DRUG tipifarnib
- DRUG temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2006-04 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00335764
The ClinicalTrials.gov registry entry for NCT00335764 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which erlotinib hydrochloride is the first listed.
NCT00335764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00335764 about?
NCT00335764 is a clinical study titled "Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma". This phase I/II trial is studying the side effects and best dose of erlotinib, tipifarnib, and temsirolimus when given together with sorafenib and to see how well they work in treating patients with recurrent glioblastoma multiforme or gliosarcoma. Sorafenib, erlotinib, tipifarnib, and temsirolimus ...
What is the current status of trial NCT00335764?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2006-04. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00335764?
The interventions under investigation include: erlotinib hydrochloride (DRUG), sorafenib tosylate (DRUG), tipifarnib (DRUG), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00335764?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.